These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 15501526

  • 1. Ac His1 [D-Phe2, K15, R16, L27] VIP (3-7)/GRF (8-27)--a VPAC1 receptor antagonist--is an inverse agonist on two constitutively active truncated VPAC1 receptors.
    Vertongen P, Langlet C, Langer I, Gaspard N, Robberecht P.
    Peptides; 2004 Nov; 25(11):1943-9. PubMed ID: 15501526
    [Abstract] [Full Text] [Related]

  • 2. Elucidation of the vasoactive intestinal peptide pharmacophore for VPAC(2) receptors in human and rat and comparison to the pharmacophore for VPAC(1) receptors.
    Igarashi H, Ito T, Pradhan TK, Mantey SA, Hou W, Coy DH, Jensen RT.
    J Pharmacol Exp Ther; 2002 Nov; 303(2):445-60. PubMed ID: 12388623
    [Abstract] [Full Text] [Related]

  • 3. Asn229 in the third helix of VPAC1 receptor is essential for receptor activation but not for receptor phosphorylation and internalization: comparison with Asn216 in VPAC2 receptor.
    Nachtergael I, Gaspard N, Langlet C, Robberecht P, Langer I.
    Cell Signal; 2006 Dec; 18(12):2121-30. PubMed ID: 16650965
    [Abstract] [Full Text] [Related]

  • 4. Two tyrosine residues in the first transmembrane helix of the human vasoactive intestinal peptide receptors play a role in supporting the active conformation.
    Perret J, Vertongen P, Solano RM, Langer I, Cnudde J, Robberecht P, Waelbroeck M.
    Br J Pharmacol; 2002 Aug; 136(7):1042-8. PubMed ID: 12145104
    [Abstract] [Full Text] [Related]

  • 5. Different vasoactive intestinal polypeptide receptor domains are involved in the selective recognition of two VPAC(2)-selective ligands.
    Juarranz MG, Van Rampelbergh J, Gourlet P, De Neef P, Cnudde J, Robberecht P, Waelbroeck M.
    Mol Pharmacol; 1999 Dec; 56(6):1280-7. PubMed ID: 10570056
    [Abstract] [Full Text] [Related]

  • 6. Characterization of a novel VPAC(1) selective agonist and identification of the receptor domains implicated in the carboxyl-terminal peptide recognition.
    Van Rampelbergh J, Juarranz MG, Perret J, Bondue A, Solano RM, Delporte C, De Neef P, Robberecht P, Waelbroeck M.
    Br J Pharmacol; 2000 Jun; 130(4):819-26. PubMed ID: 10864888
    [Abstract] [Full Text] [Related]

  • 7. Mutational analysis of the human vasoactive intestinal peptide receptor subtype VPAC(2): role of basic residues in the second transmembrane helix.
    Vertongen P, Solano RM, Perret J, Langer I, Robberecht P, Waelbroeck M.
    Br J Pharmacol; 2001 Aug; 133(8):1249-54. PubMed ID: 11498510
    [Abstract] [Full Text] [Related]

  • 8. Serine 447 in the carboxyl tail of human VPAC1 receptor is crucial for agonist-induced desensitization but not internalization of the receptor.
    Marie JC, Rouyer-Fessard C, Couvineau A, Nicole P, Devaud H, El Benna J, Laburthe M.
    Mol Pharmacol; 2003 Dec; 64(6):1565-74. PubMed ID: 14645688
    [Abstract] [Full Text] [Related]

  • 9. Mutations in the carboxy-terminus of the third intracellular loop of the human recombinant VPAC1 receptor impair VIP-stimulated [Ca2+]i increase but not adenylate cyclase stimulation.
    Langer I, Robberecht P.
    Cell Signal; 2005 Jan; 17(1):17-24. PubMed ID: 15451021
    [Abstract] [Full Text] [Related]

  • 10. Evidence for a direct interaction between the Thr11 residue of vasoactive intestinal polypeptide and Tyr184 located in the first extracellular loop of the VPAC2 receptor.
    Nachtergael I, Vertongen P, Langer I, Perret J, Robberecht P, Waelbroeck M.
    Biochem J; 2003 Mar 15; 370(Pt 3):1003-9. PubMed ID: 12475394
    [Abstract] [Full Text] [Related]

  • 11. Effect of inactivating mutations on phosphorylation and internalization of the human VPAC2 receptor.
    Langer I, Langlet C, Robberecht P.
    J Mol Endocrinol; 2005 Apr 15; 34(2):405-14. PubMed ID: 15821106
    [Abstract] [Full Text] [Related]

  • 12. A small sequence in the third intracellular loop of the VPAC(1) receptor is responsible for its efficient coupling to the calcium effector.
    Langer I, Vertongen P, Perret J, Waelbroeck M, Robberecht P.
    Mol Endocrinol; 2002 May 15; 16(5):1089-96. PubMed ID: 11981043
    [Abstract] [Full Text] [Related]

  • 13. Study of species specificity in growth hormone-releasing factor (GRF) interaction with vasoactive intestinal peptide (VIP) receptors using GRF and intestinal VIP receptors from rat and human: evidence that Ac-Tyr1hGRF is a competitive VIP antagonist in the rat.
    Laburthe M, Couvineau A, Rouyer-Fessard C.
    Mol Pharmacol; 1986 Jan 15; 29(1):23-7. PubMed ID: 3003561
    [Abstract] [Full Text] [Related]

  • 14. Pharmacological properties of Chinese hamster ovary cells coexpressing two vasoactive intestinal peptide receptors (hVPAC1 and hVPAC2).
    Langer I, Gaspard N, Robberecht P.
    Br J Pharmacol; 2006 Aug 15; 148(8):1051-9. PubMed ID: 16783404
    [Abstract] [Full Text] [Related]

  • 15. Vasoactive intestinal polypeptide receptor VPAC(1) subtype is predominant in rat prostate membranes.
    Juarranz MG, De Neef P, Robberecht P.
    Prostate; 1999 Sep 15; 41(1):1-6. PubMed ID: 10440869
    [Abstract] [Full Text] [Related]

  • 16. Spatial approximation between the C-terminus of VIP and the N-terminal ectodomain of the VPAC1 receptor.
    Ceraudo E, Tan YV, Couvineau A, Lacapere JJ, Laburthe M.
    Ann N Y Acad Sci; 2006 Jul 15; 1070():180-4. PubMed ID: 16888162
    [Abstract] [Full Text] [Related]

  • 17. VIP enhances synaptic transmission to hippocampal CA1 pyramidal cells through activation of both VPAC1 and VPAC2 receptors.
    Cunha-Reis D, Ribeiro JA, Sebastião AM.
    Brain Res; 2005 Jul 05; 1049(1):52-60. PubMed ID: 15935995
    [Abstract] [Full Text] [Related]

  • 18. Tryptophan 67 in the human VPAC(1) receptor: crucial role for VIP binding.
    Nicole P, Maoret JJ, Couvineau A, Momany FA, Laburthe M.
    Biochem Biophys Res Commun; 2000 Sep 24; 276(2):654-9. PubMed ID: 11027527
    [Abstract] [Full Text] [Related]

  • 19. Vasoactive intestinal peptide (VIP) stimulates [Ca2+]i and cyclic AMPin CHO cells expressing Galpha16.
    Langer I, Perret J, Vertongen P, Waelbroeck M, Robberecht P.
    Cell Calcium; 2001 Oct 24; 30(4):229-34. PubMed ID: 11587546
    [Abstract] [Full Text] [Related]

  • 20. Development of selective agonists and antagonists for the human vasoactive intestinal polypeptide VPAC(2) receptor.
    Moreno D, Gourlet P, De Neef P, Cnudde J, Waelbroeck M, Robberecht P.
    Peptides; 2000 Oct 24; 21(10):1543-9. PubMed ID: 11068102
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.